Imunon(IMNN)

Search documents
Imunon(IMNN) - 2021 Q3 - Earnings Call Transcript
2021-11-15 19:41
Celsion Corporation (CLSN) Q3 2021 Earnings Conference Call November 15, 2021 11:00 AM ET Company Participants Kim Golodetz – HLA Michael Tardugno – Chairman, CEO and President Jeffrey Church – Chief Financial Officer Nicholas Borys – Chief Medical Officer Khursheed Anwer – Chief Science Officer Conference Call Participants Kumar Raja – Brookline Capital Markets David Bautz – Zacks Small Cap Research Mike Worth – Celsion Operator Good morning. My name is Bobby, and I will be your operator today. At this ti ...
Imunon(IMNN) - 2021 Q3 - Quarterly Report
2021-11-15 14:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-15911 CELSION CORPORATION (Exact name of Registrant as specified in its charter) (State or other ...
Imunon(IMNN) - 2021 Q2 - Earnings Call Transcript
2021-08-12 19:40
Celsion Corporation (CLSN) Q2 2021 Earnings Conference Call August 12, 2021 11:00 AM ET Company Participants Kim Golodetz - SVP and Principal Michael Tardugno - Chairman, CEO and President Nicholas Borys - Chief Medical Officer Jeffrey Church - Chief Financial Officer Khursheed Anwer - Executive VP & Chief Scientific Officer Conference Call Participants Kumar Raja - Brookline Capital Operator Please standby, and good morning. My name is Nick, and I will be your operator today. At this time, I would like to ...
Imunon(IMNN) - 2021 Q2 - Quarterly Report
2021-08-12 13:02
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-15911 CELSION CORPORATION (Exact name of Registrant as specified in its charter) Delaware 52-1256615 ( ...
Imunon(IMNN) - 2021 Q1 - Earnings Call Transcript
2021-05-14 17:54
Celsion Corporation (CLSN) Q1 2021 Earnings Conference Call May 14, 2021 10:00 AM ET Company Participants Kim Golodetz - IR Michael Tardugno - Chairman, CEO and President Jeff Church - CFO Khursheed Anwer - Chief Science Officer Nicholas Borys - Chief Medical Officer Conference Call Participants Kumaraguru Raja - Brookline Capital Markets Operator Please stand by. Good morning. My name is Olivia and I will be your operator today. At this time, I'd like to welcome you all to Celsion’s First Quarter 2021 Fina ...
Imunon(IMNN) - 2021 Q1 - Quarterly Report
2021-05-14 13:05
Commission file number: 001-15911 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ CELSION CORPORATION (Exact name of Registrant as specified in its charter) (State or other ...
Imunon(IMNN) - 2020 Q4 - Earnings Call Transcript
2021-03-19 18:02
Celsion Corporation (CLSN) Q4 2020 Earnings Conference Call March 19, 2021 11:00 AM ET Company Participants Kim Golodetz - Investor Relations Michael Tardugno - Chairman, CEO and President Jeff Church - Chief Financial Officer Khursheed Anwer - Chief Science Officer Nicholas Borys - Chief Medical Officer Operator Ladies and gentlemen, good morning. My name is David, and I will be your operator today. At this time, I would like to welcome you all to Celsion’s 2020 Financial Results Conference Call. All lines ...
Imunon(IMNN) - 2020 Q4 - Annual Report
2021-03-19 13:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-15911 CELSION CORPORATION (Exact Name of Registrant as Specified in Its Charter) DELAWARE 52-1256615 FORM 10-K (State or ...
Imunon(IMNN) - 2020 Q3 - Earnings Call Transcript
2020-11-16 19:59
Celsion Corporation (CLSN) Q3 2020 Results Earnings Conference Call November 16, 2020 11:00 AM ET Company Participants Michael Tardugno - Chairman, President and CEO Jeff Church - Executive Vice President and CFO Dr. Nicholas Borys - Executive Vice President and CMO Kim Golodetz - LHA Investor Relations Conference Call Participants Hartaj Singh - Oppenheimer Raj Kumar - Brookline Capital Markets Operator Please standby. Good morning. My name is Casey, and I will be your operator today. At this time, I would ...
Imunon(IMNN) - 2020 Q3 - Quarterly Report
2020-11-16 13:57
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-15911 CELSION CORPORATION (Exact name of registrant as specified in its charter) Delaware 52-1256615 (State or other jurisdiction of incorporation or org ...